Comparative Pharmacology
Head-to-head clinical analysis: ESZOPICLONE versus LUNESTA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ESZOPICLONE versus LUNESTA.
ESZOPICLONE vs LUNESTA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Non-benzodiazepine sedative-hypnotic that binds to GABA-A receptors at a site distinct from benzodiazepine binding site, enhancing GABAergic inhibition and increasing chloride ion conductance.
Nonbenzodiazepine hypnotic that binds to GABA-A receptors at the benzodiazepine binding site, enhancing GABAergic inhibitory neurotransmission.
1 mg, 2 mg, or 3 mg orally once daily immediately before bedtime; maximum dose 3 mg/day.
1 mg, 2 mg, or 3 mg orally once immediately before bedtime; not to exceed 3 mg/day.
None Documented
None Documented
6 hours (range 5-8 hours); at steady state in elderly or hepatic impairment, half-life may be prolonged to approximately 9 hours.
Clinical Note
moderateEszopiclone + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Eszopiclone is combined with Fluticasone propionate."
Clinical Note
moderateEszopiclone + Teriflunomide
"The metabolism of Teriflunomide can be decreased when combined with Eszopiclone."
Clinical Note
moderateEszopiclone + Haloperidol
"The risk or severity of adverse effects can be increased when Eszopiclone is combined with Haloperidol."
Clinical Note
moderateEszopiclone + Sulfisoxazole
Terminal elimination half-life is approximately 6 hours in young adults and about 9 hours in elderly patients. This supports once-nightly dosing for insomnia.
Renal: 75% (as metabolites, primarily N-desmethyleszopiclone and eszopiclone-N-oxide); Fecal: approximately 10%; less than 10% excreted unchanged in urine.
Primarily hepatic metabolism via CYP3A4 and CYP2E1; renal excretion of metabolites accounts for approximately 80% of total clearance, with about 2-4% excreted unchanged in urine. Fecal excretion contributes less than 10%.
Category A/B
Category C
Non-Benzodiazepine Hypnotic
Non-Benzodiazepine Hypnotic
"The metabolism of Sulfisoxazole can be decreased when combined with Eszopiclone."